Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TERT | O14746 | 2/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25826713 | 0.97 | NCF1 (0.41) | NCF1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL25826715 | 0.89 | MAPT (0.52) | NCF1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL25824152 | 0.85 | ALDH1A1 (0.54) | NCF1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL23999691 | 0.84 | IP6K1 (0.46) | NCF1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL24009992 | 0.82 | ALDH1A1 (0.50) | NCF1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL24003938 | 0.81 | IP6K1 (0.43) | NCF1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL25826717 | 0.80 | IP6K1 (0.48) | ALDH1A1MEN1KMT2ATERTIP6K1 | |
| SCHEMBL25826718 | 0.77 | IP6K1 (0.45) | ALDH1A1MEN1KMT2AIP6K1GAA | |
| SCHEMBL23999574 | 0.77 | TERT (0.50) | NCF1ALDH1A1KDM4EMEN1MAPT | |
| SCHEMBL25820170 | 0.76 | NCF1 (0.44) | NCF1ALDH1A1KDM4EMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | NCF1 1223/4885ALDH1A1 4541/4885KDM4E 4095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.